The mitochondrial enzyme glutaminase in particular is under intense investigation in many tumor models [35], with an immense amount of time invested in the development of selective and non-toxic small-molecule glutaminase inhibitors with superior metabolic stability and pharmacodynamics. Here, GLS is linked to neoplasm.